-
Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells.
Scientific reports 20160101
-
Harmine Induces Adipocyte Thermogenesis through RAC1-MEK-ERK-CHD4 Axis.
Scientific reports 20160101
-
Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma.
Molecular cancer research : MCR 20141001
-
Synergistic induction of human cathelicidin antimicrobial peptide gene expression by vitamin D and stilbenoids.
Molecular nutrition & food research 20140301
-
Flavanoids induce expression of the suppressor of cytokine signalling 3 (SOCS3) gene and suppress IL-6-activated signal transducer and activator of transcription 3 (STAT3) activation in vascular endothelial cells.
The Biochemical journal 20130901
-
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters 20130801
-
Optimization of allosteric MEK inhibitors. Part 1: Venturing into underexplored SAR territories.
Bioorganic & medicinal chemistry letters 20130415
-
MEK and the inhibitors: from bench to bedside.
Journal of hematology & oncology 20130101
-
Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models.
Clinical cancer research : an official journal of the American Association for Cancer Research 20121001
-
Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.
International journal of oncology 20120801
-
Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification.
Molecular cancer therapeutics 20120701
-
A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.
Investigational new drugs 20120601
-
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells.
British journal of cancer 20120508
-
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.
Cell 20120413
-
The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition.
British journal of cancer 20120410
-
Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055).
Cancer research 20120401
-
Cancer: Clinical trials unite mice and humans.
Nature 20120328
-
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.
Nature 20120318
-
Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
Clinical cancer research : an official journal of the American Association for Cancer Research 20120315
-
The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.
British journal of cancer 20120227
-
Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.
Clinical cancer research : an official journal of the American Association for Cancer Research 20120215
-
The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells.
The Journal of clinical endocrinology and metabolism 20120201
-
Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro.
Endocrine-related cancer 20120201
-
MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.
Molecular cancer therapeutics 20120201
-
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 20120115
-
Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.
PloS one 20120101
-
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 20111201
-
Small molecule inhibition of the steroid receptor coactivators, SRC-3 and SRC-1.
Molecular endocrinology (Baltimore, Md.) 20111201
-
Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2.
Blood 20111110
-
Comprehensive analysis of kinase inhibitor selectivity.
Nature biotechnology 20111030
-
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens.
Investigational new drugs 20111001
-
Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma.
Nature genetics 20110925
-
Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death.
Cancer biology & therapy 20110801
-
Enhancement of 5-fluorouracil-induced in vitro and in vivo radiosensitization with MEK inhibition.
Clinical cancer research : an official journal of the American Association for Cancer Research 20110801
-
Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2.
Neuro-oncology 20110701
-
Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110610
-
NSCLC drug targets acquire new visibility.
Journal of the National Cancer Institute 20110302
-
Regulation of mesenchymal stem cell activity by endothelial cells.
Stem cells and development 20110301
-
Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice.
Cancer chemotherapy and pharmacology 20110201
-
Could HBx protein expression affect signal pathway inhibition by gefitinib or selumetinib, a MEK inhibitor, in hepatocellular carcinoma cell lines?
Journal of Korean medical science 20110201
-
EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling.
Cancer cell 20110118
-
MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy.
Cancer research 20110115
-
Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
PloS one 20110101
-
Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 20101215
-
Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
Chemistry & biology 20101124
-
A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20101001
-
Inhibition of MEK/ERK signaling induces apoptosis of acute myelogenous leukemia cells via inhibition of eukaryotic initiation factor 4E-binding protein 1 and down-regulation of Mcl-1.
Apoptosis : an international journal on programmed cell death 20100701
-
AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma.
Cancer 20100301
-
The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 20100301
-
Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders.
Clinical cancer research : an official journal of the American Association for Cancer Research 20100201
-
Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244.
Neurobiology of disease 20100101
-
AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
Journal of hepatology 20100101
-
Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim.
PloS one 20100101
-
Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.
PloS one 20100101
-
Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.
British journal of cancer 20091117
-
Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer.
The Journal of clinical endocrinology and metabolism 20091001
-
A combined, rational approach towards inhibition of the MEK-ERK and mTOR pathways in pancreatic ductal adenocarcinoma: promise or deja vu?
Cancer biology & therapy 20091001
-
Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models.
Cancer biology & therapy 20091001
-
Blockade of MEK signaling potentiates 5-Aza-2'-deoxycytidine-induced apoptosis and upregulation of p21(waf1) in acute myelogenous leukemia cells.
International journal of cancer 20090901
-
Inhibition of MEK signaling enhances the ability of cytarabine to induce growth arrest and apoptosis of acute myelogenous leukemia cells.
Apoptosis : an international journal on programmed cell death 20090901
-
AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer.
Molecular cancer therapeutics 20090901
-
Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells.
Molecular cancer therapeutics 20090901
-
Trial offers early test case for personalized medicine.
Journal of the National Cancer Institute 20090204
-
Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell.
Leukemia 20080701
-
Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway.
Clinical cancer research : an official journal of the American Association for Cancer Research 20080615
-
Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene.
Leukemia research 20080601
-
BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.
The Journal of clinical endocrinology and metabolism 20080601
-
The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 20080101
-
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
Blood 20070901
-
AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma.
Molecular cancer therapeutics 20070901
-
AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models.
Molecular cancer therapeutics 20070801
-
ZD6474 induces growth arrest and apoptosis of human leukemia cells, which is enhanced by concomitant use of a novel MEK inhibitor, AZD6244.
Leukemia 20070601
-
Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor.
Clinical cancer research : an official journal of the American Association for Cancer Research 20070301
-
Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma.
Molecular cancer therapeutics 20070101
-
Targeted agents for the treatment of advanced renal cell carcinoma.
Current drug targets 20051101
-
Mutations of the BRAF gene in human cancer.
Nature 20020627